Table 1.
Patient and treatment characteristics
| Characteristics | Varieties | BEAV | Non BEAV | P value | ||
|---|---|---|---|---|---|---|
|
| ||||||
| N=20 N% | N=21 N% | |||||
| Median age | 56 [35-67] | 58 [35-80] | ||||
| Gender | 0.4021 | |||||
| Male | 14 | 70.0% | 18 | 85.7% | ||
| Female | 6 | 30.0% | 3 | 14.3% | ||
| Hepatitis virus | 0.6381 | |||||
| HBV | 15 | 75.0% | 18 | 85.7% | ||
| N | 5 | 25.0% | 3 | 14.3% | ||
| AFP (ng/mL) | 0.6571 | |||||
| <400 | 13 | 65.0% | 16 | 76.2% | ||
| ≥400 | 7 | 35.0% | 5 | 23.8% | ||
| Child-Pugh (class) | 0.2381 | |||||
| A | 13 | 65.0% | 18 | 85.7% | ||
| B | 7 | 35.0% | 3 | 14.3% | ||
| Tumor distribution | 0.0411 | |||||
| Solitary | 7 | 35.0% | 1 | 4.8% | ||
| Multifocal | 13 | 65.0% | 20 | 95.2% | ||
| ECOG score | 0.9061 | |||||
| 0 | 8 | 40.0% | 7 | 33.3% | ||
| 1 | 12 | 60.0% | 14 | 66.7% | ||
| TNM (stage) | 0.0691 | |||||
| IVA | 9 | 45.0% | 3 | 14.3% | ||
| IVB | 11 | 55.0% | 18 | 85.7% | ||
| Previous therapy | First-line treatment | |||||
| Sorafenib | 3 | 15.0% | ||||
| Lenvatinib | 17 | 85.0% | 21 | 100% | ||
| Second-line therapy | ||||||
| PD-1 (Tirelizumab) | 16 | 80.0% | 18 | 85.7% | ||
| PDL1 (Durvalumab) | 4 | 20.0% | 3 | 14.3% | ||
| Third-line treatment | ||||||
| Bevacizumab | 20 | 100.0% | 0 | 0% | ||
| Metastatic site | Intrahepatic | 8 | 40.0% | 20 | 95.2% | |
| Lymph nodes | 8 | 40.0% | 7 | 33.3% | ||
| Lung | 6 | 30.0% | 3 | 14.3% | ||
| Bone | 5 | 25.0% | 3 | 14.3% | ||
1
χ 2 test.
HBV, hepatitis B virus; N, no HBV infection; AFP, alpha-fetoprotein; TNM (stage), American Joint Committee on Cancer-Tumor Node Metastasis staging; ECOG score, American Joint Committee on Cancer-Tumor Node Metastasis staging.